EA201400274A1 - Связующая молекула, обладающая нейтрализующей активностью в отношении вируса гриппа а, полученная из в-клеток человека - Google Patents
Связующая молекула, обладающая нейтрализующей активностью в отношении вируса гриппа а, полученная из в-клеток человекаInfo
- Publication number
- EA201400274A1 EA201400274A1 EA201400274A EA201400274A EA201400274A1 EA 201400274 A1 EA201400274 A1 EA 201400274A1 EA 201400274 A EA201400274 A EA 201400274A EA 201400274 A EA201400274 A EA 201400274A EA 201400274 A1 EA201400274 A1 EA 201400274A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- virus
- influenza
- activity against
- neutralizing activity
- cells
- Prior art date
Links
- 230000003472 neutralizing effect Effects 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 title 1
- 241000712461 unidentified influenza virus Species 0.000 title 1
- 241000712431 Influenza A virus Species 0.000 abstract 6
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
Abstract
Изобретение относится к связывающей молекуле, обладающей нейтрализующей активностью в отношении вируса гриппа А, полученной из В-клетки человека, при этом указанной связывающей молекулой, обладающей нейтрализующей активностью в отношении вируса гриппа А, в соответствии с настоящим изобретением является связывающая молекула, которая получена из В-клетки, отобранной из крови пациента, инфицированного вирусом гриппа А, и которая обладает нейтрализующей активностью в отношении вирусов гриппа А, и, следовательно, пригодна для профилактики и лечения заболеваний, вызванных вирусом гриппа А, а также может быть пригодна для диагностики вируса гриппа А с использованием указанной связывающей молекулы в соответствии с настоящим изобретением.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110099646 | 2011-09-30 | ||
PCT/KR2012/007835 WO2013048153A2 (ko) | 2011-09-30 | 2012-09-27 | 인간 b 세포에서 생산된 인플루엔자 a 바이러스 중화 활성을 가지는 결합 분자 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201400274A1 true EA201400274A1 (ru) | 2014-09-30 |
EA026527B1 EA026527B1 (ru) | 2017-04-28 |
Family
ID=47996632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201400274A EA026527B1 (ru) | 2011-09-30 | 2012-09-27 | Связующая молекула, обладающая нейтрализующей активностью в отношении вируса гриппа а, полученная из в-клеток человека |
Country Status (12)
Country | Link |
---|---|
US (2) | US9475861B2 (ru) |
EP (1) | EP2762491B1 (ru) |
JP (1) | JP5998222B2 (ru) |
KR (1) | KR101514682B1 (ru) |
CN (1) | CN104011077B (ru) |
AU (1) | AU2012316930B2 (ru) |
CA (2) | CA2900712A1 (ru) |
EA (1) | EA026527B1 (ru) |
ES (1) | ES2641257T3 (ru) |
IL (1) | IL231779B (ru) |
MX (1) | MX350282B (ru) |
WO (1) | WO2013048153A2 (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
KR20140118682A (ko) * | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 a 바이러스 중화 결합 분자를 포함하는 조성물 |
CN104892753B (zh) * | 2014-03-07 | 2019-11-29 | 神州细胞工程有限公司 | 一种中和人感染h7n9甲型流感病毒的抗体及其用途 |
WO2016010160A1 (ja) * | 2014-07-18 | 2016-01-21 | 国立感染症研究所長が代表する日本国 | 抗インフルエンザウイルス抗体及びその利用 |
US20180008702A1 (en) * | 2014-12-05 | 2018-01-11 | Celltrion Inc. | Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same |
WO2016089181A1 (ko) * | 2014-12-05 | 2016-06-09 | (주)셀트리온 | 1 이상의 인플루엔자 바이러스 중화 결합 분자를 포함하는 애주번트 조성물 및 이를 포함하는 백신 조성물 |
EP3280730B1 (en) * | 2015-04-08 | 2024-01-03 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
EP3374390A1 (en) | 2015-11-13 | 2018-09-19 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
CN110192096B (zh) * | 2016-04-21 | 2022-04-19 | 艾珀尔有限公司 | 生物体物质检测用设备和检测装置、离子电流的测定方法以及生物体物质的识别方法 |
CN109803640B (zh) * | 2016-08-10 | 2022-01-04 | 赛特瑞恩股份有限公司 | 稳定的液体抗流感病毒抗体医药调配物 |
KR102320280B1 (ko) * | 2018-05-31 | 2021-11-29 | 주식회사 센트릭스바이오 | CD300c의 발현 억제제 또는 활성 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물 |
KR20200060969A (ko) * | 2018-11-23 | 2020-06-02 | (주)셀트리온 | 인플루엔자 바이러스 질환을 치료하기 위한 투여 요법 |
JP2022521819A (ja) | 2019-03-25 | 2022-04-12 | ビステラ, インコーポレイテッド | インフルエンザを処置および予防するための組成物および方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090068637A1 (en) | 2006-01-26 | 2009-03-12 | Ningshao Xia | Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and use thereof |
US8148085B2 (en) * | 2006-05-15 | 2012-04-03 | Sea Lane Biotechnologies, Llc | Donor specific antibody libraries |
EP2522678A1 (en) * | 2006-05-15 | 2012-11-14 | Sea Lane Biotechnologies, LLC | Neutralizing antibodies to influenza viruses |
US20100040635A1 (en) * | 2008-03-28 | 2010-02-18 | Sea Lane Biotechnologies | Neutralizing antibodies to influenza viruses |
CA2733218A1 (en) | 2008-07-25 | 2010-01-28 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
US20120128671A1 (en) | 2009-05-13 | 2012-05-24 | Lawrence Horowitz | Neutralizing molecules to influenza viruses |
CA2787940C (en) * | 2010-01-27 | 2020-01-07 | Massachusetts Institute Of Technology | Engineered polypeptide agents for targeted broad spectrum influenza neutralization |
MX338758B (es) * | 2010-03-08 | 2016-04-29 | Celltrion Inc | Anticuerpos monoclonales humanos, derivados de celulas b humanas, y que tienen actividad neutralizante contra el virus de la influenza a. |
EP2596017B1 (en) * | 2010-07-22 | 2019-04-03 | John W. Schrader | Cross-protective antibody against influenza viral infection |
EP2663334A4 (en) * | 2011-01-10 | 2016-01-13 | Univ Emory | ANTIBODIES AGAINST INFLUENZA |
-
2012
- 2012-09-27 KR KR1020120107512A patent/KR101514682B1/ko active IP Right Grant
- 2012-09-27 US US14/348,284 patent/US9475861B2/en active Active
- 2012-09-27 EA EA201400274A patent/EA026527B1/ru not_active IP Right Cessation
- 2012-09-27 WO PCT/KR2012/007835 patent/WO2013048153A2/ko active Application Filing
- 2012-09-27 AU AU2012316930A patent/AU2012316930B2/en active Active
- 2012-09-27 JP JP2014533206A patent/JP5998222B2/ja active Active
- 2012-09-27 CA CA2900712A patent/CA2900712A1/en not_active Abandoned
- 2012-09-27 MX MX2014003745A patent/MX350282B/es active IP Right Grant
- 2012-09-27 ES ES12835569.0T patent/ES2641257T3/es active Active
- 2012-09-27 CN CN201280047234.0A patent/CN104011077B/zh active Active
- 2012-09-27 EP EP12835569.0A patent/EP2762491B1/en active Active
- 2012-09-27 CA CA2850720A patent/CA2850720C/en active Active
-
2014
- 2014-03-27 IL IL231779A patent/IL231779B/en active IP Right Grant
-
2016
- 2016-09-08 US US15/259,823 patent/US9856312B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2900712A1 (en) | 2013-04-04 |
EA026527B1 (ru) | 2017-04-28 |
CA2850720C (en) | 2016-03-29 |
ES2641257T3 (es) | 2017-11-08 |
JP2014530008A (ja) | 2014-11-17 |
MX2014003745A (es) | 2014-07-22 |
CA2850720A1 (en) | 2013-04-04 |
US9856312B2 (en) | 2018-01-02 |
JP5998222B2 (ja) | 2016-09-28 |
WO2013048153A3 (ko) | 2013-05-23 |
EP2762491B1 (en) | 2017-07-05 |
US20170037113A1 (en) | 2017-02-09 |
CN104011077A (zh) | 2014-08-27 |
CN104011077B (zh) | 2017-06-20 |
EP2762491A4 (en) | 2015-05-20 |
EP2762491A2 (en) | 2014-08-06 |
IL231779A0 (en) | 2014-05-28 |
MX350282B (es) | 2017-09-01 |
WO2013048153A2 (ko) | 2013-04-04 |
AU2012316930B2 (en) | 2016-06-09 |
US20140234336A1 (en) | 2014-08-21 |
KR20130035916A (ko) | 2013-04-09 |
KR101514682B1 (ko) | 2015-04-23 |
IL231779B (en) | 2019-01-31 |
AU2012316930A1 (en) | 2014-04-17 |
US9475861B2 (en) | 2016-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201400274A1 (ru) | Связующая молекула, обладающая нейтрализующей активностью в отношении вируса гриппа а, полученная из в-клеток человека | |
EA201400855A1 (ru) | Моноклональные антитела человека, полученные из в-клеток человека и обладающие нейтрализующей активностью против вирусов гриппа а | |
CY1124043T1 (el) | Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων | |
EA201490588A1 (ru) | Способы лечения вируса гепатита с | |
EA201391019A1 (ru) | Соединения и способы для модуляции киназ, а также показания к их применению | |
EA201491423A1 (ru) | Соединения имидазопирролидинонов | |
EA201300558A1 (ru) | Соединения и способы для купирования боли | |
EA201291336A1 (ru) | Замещенные 5-фтор-1н-пиразолопиридины и их применение | |
EA201590343A1 (ru) | Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
EA201791916A1 (ru) | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения | |
EA201291300A1 (ru) | Производные нафт-2-илуксусной кислоты для лечения спида | |
EA201301173A1 (ru) | Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования | |
EA201190259A1 (ru) | Противовирусные соединения | |
EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
EA201390576A1 (ru) | Противовирусные соединения | |
EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
EA201201030A1 (ru) | 5-алкинилпиримидины | |
MX2015009416A (es) | Anticuerpos humanos de la proteina f del virus respiratorio sincitial y metodos de uso de estos. | |
EA201590197A1 (ru) | Соединения для лечения парамиксовирусных вирусных инфекций | |
EA201790963A1 (ru) | Противовирусные соединения | |
EA201400976A1 (ru) | Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена | |
EA201690687A1 (ru) | Ингибиторы репликации вируса иммунодефицита | |
EA201590703A1 (ru) | Ингибиторы mek при лечении вирусных заболеваний | |
MX2013001906A (es) | Metodos para reducir la concentracion de lactato en la sangre. | |
EA201490721A1 (ru) | Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |